Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.tips.2020.04.005 http://scihub22266oqcxt.onion/10.1016/j.tips.2020.04.005 32416934!7177145!32416934     free     free     free       Trends+Pharmacol+Sci 2020 ; 41 (7): 464-474 Nephropedia Template TP {{tp|p=32416934|t=2020. Emerging New Concepts of Degrader Technologies |pdf=|usr=}}{{32416934}} gab.com Text Emerging New Concepts of Degrader Technologies JO: Trends Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32416934 #FOAvip Traditional drug discovery focuses on identifying direct inhibitors of target proteins. This typically relies on a measurable biochemical readout and accessible binding sites whose occupancy influences the function of the target protein. These requirements preclude many disease-causing proteins from being 'druggable' targets, and these proteins are categorized as 'undruggable'. The proteolysis-targeting chimera (PROTAC) technology provides powerful tools to degrade these undruggable targets and has become a promising approach for drug discovery. However, the PROTAC technology has some limitations, and emerging new degrader technologies may greatly broaden the spectrum of targets that could be selectively degraded by harnessing a second major degradation pathway in cells. We review key emerging technologies that exploit the lysosomal degradation pathway and discuss their potential applications and limitations. Twit Text FOAVip Emerging New Concepts of Degrader Technologies ????Trends Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32416934 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32416934 #FOAvip English Wikipedia <ref>{{Cite pmid|32416934}}</ref> Emerging New Concepts of Degrader Technologies #MMPMID32416934 Ding Y; Fei Y; Lu B Trends Pharmacol Sci 2020[Jul]; 41 (7): 464-474 PMID32416934show ga Traditional drug discovery focuses on identifying direct inhibitors of target proteins. This typically relies on a measurable biochemical readout and accessible binding sites whose occupancy influences the function of the target protein. These requirements preclude many disease-causing proteins from being 'druggable' targets, and these proteins are categorized as 'undruggable'. The proteolysis-targeting chimera (PROTAC) technology provides powerful tools to degrade these undruggable targets and has become a promising approach for drug discovery. However, the PROTAC technology has some limitations, and emerging new degrader technologies may greatly broaden the spectrum of targets that could be selectively degraded by harnessing a second major degradation pathway in cells. We review key emerging technologies that exploit the lysosomal degradation pathway and discuss their potential applications and limitations. |*Drug Discovery[MESH] |*Proteins/metabolism[MESH] |Humans[MESH] |Proteolysis[MESH]Emerging New Concepts of Degrader Technologies (epmc).pdf DeepDyve Pubget Overpricing